Is nighttime blood pressure important in cardiovascular risk assessment in coronary atherosclerosis?

W Sobiczewski1, M Wirtwein2, M Gruchala1

  • 1I Department of Cardiology, Medical University of Gdansk, Gdansk, Poland.

Insights

Elevated nighttime blood pressure (BP) is linked to increased major adverse cardiac events (MACE) in hypertensive patients with coronary atherosclerosis. Monitoring nocturnal BP may improve cardiovascular risk assessment in this population.

Area of Science:

  • Cardiology
  • Hypertension Research
  • Preventive Cardiology

Background:

  • Nighttime blood pressure (BP) is crucial for cardiovascular risk assessment in the general population.
  • The prognostic significance of elevated nighttime BP in hypertensive patients with established coronary atherosclerosis remains unclear.
  • The PROGNOSIS study investigated the association between abnormal nighttime BP and major adverse cardiac events (MACE) in this specific patient group.

Discussion:

  • A higher prevalence of abnormal nighttime BP (≥120/70 mmHg) was observed in patients who experienced MACE compared to those who did not.
  • Cumulative incidence curves indicated a significantly higher risk of MACE during the follow-up period for individuals with abnormal nighttime BP.
  • These findings suggest that elevated nighttime BP is an independent contributor to cardiovascular risk in patients with confirmed coronary atherosclerosis.

Key Insights:

  • Abnormal nighttime BP is more prevalent in hypertensive patients with coronary atherosclerosis who experience MACE.
  • Hypertensive patients with coronary atherosclerosis and elevated nighttime BP face a greater risk of MACE.
  • Nighttime BP monitoring can be a valuable tool for risk stratification in patients with coronary artery disease.

Outlook:

  • Further research is warranted to elucidate the mechanisms underlying the association between nighttime BP and MACE.
  • Integrating nighttime BP monitoring into routine clinical practice may enhance cardiovascular risk prediction in patients with coronary atherosclerosis.
  • Investigating therapeutic strategies targeting nighttime hypertension could potentially reduce MACE in this vulnerable population.

Related Concept Videos

Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response01:15

Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response

Circadian rhythms are cyclic changes that are crucial in plasma drug concentrations. Various standard circadian parameters, including core body temperature, heart rate, and other cardiovascular factors, directly impact disease states and the therapeutic response to drug therapy.
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
498
Measurement of Blood Pressure01:17

Measurement of Blood Pressure

Assessing blood pressure is a standard procedure executed in virtually all medical environments. The method utilized today was established over a hundred years ago by an innovative Russian doctor, Dr. Nikolai Korotkoff. The soft ticking noise, known as Korotkoff sounds, heard while taking blood pressure readings results from turbulent blood flow within the vessels. The apparatus required for this procedure includes a sphygmomanometer, a blood pressure cuff attached to a gauge, and a...
4.0K
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
886
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
765